Last reviewed · How we verify

QL1706 — Competitive Intelligence Brief

QL1706 (QL1706) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K/AKT pathway inhibitor. Area: Oncology.

phase 3 PI3K/AKT pathway inhibitor PI3K/AKT pathway Oncology Small molecule Live · refreshed every 30 min

Target snapshot

QL1706 (QL1706) — Fujian Cancer Hospital. QL1706 is a small molecule targeting the PI3K/AKT pathway to inhibit cancer cell growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
QL1706 TARGET QL1706 Fujian Cancer Hospital phase 3 PI3K/AKT pathway inhibitor PI3K/AKT pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K/AKT pathway inhibitor class)

  1. Fujian Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QL1706 — Competitive Intelligence Brief. https://druglandscape.com/ci/ql1706. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: